he GLP-1 world is moving extremely fast. This week’s biggest story isn’t another big weight-loss number — it’s about what happens AFTER you lose the weight.
In this update: • Lilly’s oral GLP-1 orforglipron shows strong maintenance results after injectable semaglutide and tirzepatide • Greater weight loss linked to better cardiometabolic, liver, and overall health outcomes • Important caution on oral GLP-1 pills: new data on how SNAC (the absorption enhancer) may harm the gut microbiome
We break down what this means for long-term obesity treatment and where the field is heading next.
Key topics: - Orforglipron maintenance data (ATTAIN-MAINTAIN study) - Shifting from weight loss to weight maintenance - Oral vs injectable GLP-1 differences - Gut microbiome concerns with oral formulations
Stay ahead of the curve in metabolic medicine.
Disclaimer: This is for educational and informational purposes only. Not medical advice.
Sources: Nature Medicine, Reuters, ECO 2026 / EASO reports, and recent animal data on SNAC.
Subscribe for more biohacking tips, rate us 5 stars, and join The Human 5.0 Project community for exclusive upgrades. Drop your peptide and longevity stories in the comments!
Follow on IG @Ultimatebiohacker10X
For more longevity insights and protocols, check out biohackerdepot.com – your go-to resource for cutting-edge health optimization strategies.
And if you're sourcing research peptides , peptidesphere.com has a curated selection of peptides and bioregulators with detailed info on quality and applications.
#GLP1 #Orforglipron #OralGLP1 #WeightLossMaintenance #GLP1News #Semaglutide #Tirzepatide #Ozempic #Mounjaro #ObesityTreatment #MetabolicHealth #GutMicrobiome #Biohacking #WeightLossDrugs #GLP1Maintenance#Human5.0Project #Ultimatebiohacker10X
